Simvastatin is Efficacious in Treating Cirrhosis: A Meta-analysis

Area of Science:

• Hepatology
• Pharmacology
• Clinical Medicine

Background:

• Statins offer prognostic benefits for liver cirrhosis patients by mitigating inflammation and reducing portal pressure.
• This meta-analysis investigates the efficacy of simvastatin in managing liver cirrhosis.

Purpose of the Study:

• To evaluate the clinical effectiveness and safety of simvastatin in patients diagnosed with liver cirrhosis.

Main Methods:

• A systematic literature search was conducted across PubMed, EMBASE, and Cochrane Library for relevant randomized controlled trials.
• Nine eligible randomized controlled trials, involving 648 participants, were included in the meta-analysis.

Main Results:

• Simvastatin use was associated with a significant reduction in overall mortality (RR: 0.46; P <0.01) and fatal bleeding incidence (RR: 0.35; P =0.04).
• Treatment led to significant decreases in cholesterol (MD: -31.48; P <0.01) and triglyceride levels (MD: -25.88; P =0.03).
• Simvastatin did not significantly elevate alanine aminotransferase (ALT) levels (MD: 2.34; P =0.89) or cause other adverse effects.

Conclusions:

• Simvastatin demonstrates a significant survival benefit in liver cirrhosis patients.
• The mechanism involves suppression of fatal bleeding and improved lipid profiles, with a favorable safety profile.